Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.
Acute myeloid leukemia (t-AML) is one of the worst adverse events of mitoxantrone treatment, but the exact risk in multiple sclerosis (MS) patients is not yet known. We describe a case wherein the patient developed t-AML 11 months after mitoxantrone had been discontinued. The patient was treated by polychemotherapy and autologous bone marrow transplantation with complete recovery of t-AML and stabilization of the neurological disease.
Capobianco
Marco
M
Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica, Aou S Luigi Gonzaga, Regione Gonzole 10, Orbassano TO, Italy.
Malucchi
Simona
S
Ulisciani
Stefano
S
Fava
Carmen
C
Cambrin
Giovanna Rege
GR
Avonto
Luigina
L
Saglio
Giuseppe
G
Bertolotto
Antonio
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000503:physiopathology; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012074:Remission Induction; D059005:Topoisomerase II Inhibitors; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D059005:Topoisomerase II Inhibitors; D008942:Mitoxantrone; D004250:DNA Topoisomerases, Type II